United StatesÚltimas notícias

Nathan’s Famous (NASDAQ:NATH) reported higher top-line revenue for fiscal year 2026, driven by growth in its foodservice and franchise segments, even as surging input costs chipped away at overall profit margins ahead of its planned private ownership transition.

China is planning to spend around 2 trillion yuan ($295 billion) over the next five years to build data centers across the country. Neil Campling reports on Bloomberg Television.

GSK (NYSE:GSK) has entered into a definitive agreement to acquire Nuvalent (NASDAQ:NUVL) for $10.6 billion in cash, marking a substantial expansion of the British drugmaker's oncology franchise through the purchase of three targeted lung cancer therapies.

Vertical Aerospace (NYSE:EVTL) completed the maiden piloted flight of its newest full-scale prototype aircraft, initiating an expanded flight testing campaign ahead of a major design milestone.

Novanta (NASDAQ:NOVT) has entered into a definitive agreement to acquire Riverpoint Medical, a developer and manufacturer of specialized minimally invasive surgical consumables, for an upfront cash consideration of $1.2 billion.

Powerlaw (NASDAQ:PWRL) reported a sequential increase in its monthly net asset value, driven by positive valuation updates across its investment portfolio as of the end of May.

Wei Li, chief global investment strategist at BlackRock, says there is a "healthy debate to be had" about the durability of Artificial Intelligence earnings and sees the AI trade as a "space to be selective and active."

Sam Lynton-Brown, head of global macro strategy at BNP Paribas, speaks on Blomberg Television about the outlook for Federal Reserve and European Central Bank policy.

Zai Lab (NASDAQ:ZLAB) announced that China’s National Medical Products Administration has approved its Biologics License Application for TIVDAK, an injectable therapeutic targeting adult patients with recurrent or metastatic cervical cancer.

Oculis Holding (NASDAQ:OCS) announced it has randomized the first patient in its PREDICT-1 clinical trial, marking the launch of the first genotype-based registrational study aimed at treating dry eye disease.

Intesa Sanpaolo CEO Carlo Messina discusses the lender's offer to buy Italian rival Banca Monte dei Paschi for 30.6 billion ($35.3 billion). "The only real offer now in the market is the Intesa Sanpaolo offer," Messina tells Bloomberg's Francine Lacqua, calling Banco BPM's proposal of a merger of equals merely a "love letter."

Zepp Health (NYSE:ZEPP) reported a 33.8% increase in first-quarter revenue for fiscal year 2026, driven by robust momentum from its updated premium hardware portfolio during what is traditionally a softer seasonal cycle for consumer electronics.